A9-3202

About Alpha-9 Oncology

Alpha-9 Oncology is a private, clinical-stage biotech pioneering next-generation radiopharmaceuticals for cancer. Spun out from the University of British Columbia and BC Cancer, the company leverages a proprietary, iterative design platform to create targeted therapies using isotopes like Actinium-225 and Lutetium-177. With a pipeline advancing into Phase 1 trials, strategic isotope supply agreements, and backing from top-tier investors following a Series C in 2024, Alpha-9 is positioned to accelerate the development of precision oncology treatments. The company operates dual R&D facilities in Vancouver and a corporate office in Boston.

Therapeutic Areas